Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2022-07, Vol.74 (12), p.2089-2114 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2114 |
|---|---|
| container_issue | 12 |
| container_start_page | 2089 |
| container_title | Clinical infectious diseases |
| container_volume | 74 |
| creator | Tamma, Pranita D Aitken, Samuel L Bonomo, Robert A Mathers, Amy J van Duin, David Clancy, Cornelius J |
| description | Abstract
The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase–producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of AmpC-E, CRAB, and S. maltophilia infections. Answers are presented as suggested approaches and corresponding rationales. In contrast to guidance in the previous document, published data on the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited. As such, guidance in this document is provided as “suggested approaches” based on clinical experience, expert opinion, and a review of the available literature. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Preferred and alternative treatment suggestions are provided, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Suggestions apply for both adult and pediatric populations. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 17 September 2021 and will be updated annually. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance-2.0/. |
| doi_str_mv | 10.1093/cid/ciab1013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2607302479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciab1013</oup_id><sourcerecordid>2607302479</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-d02a2c8060499c13d7a60cca7177592fce55e09180b47319f04557557859ee383</originalsourceid><addsrcrecordid>eNp9kc1u1DAQxyNERT_gxhn5BocN2HEcx8fV9oNKK4FoOUcTZ0KNYjvYzqE33qFvwnu0D8GTYLS7HJE8sq356SfN_IviNaPvGVX8gzZDLugZZfxZccIEl2UjFHue31S0Zd3y9rg4jfE7pYy1VLwojnndNrXizUnxeO1G1Mn4JZJzExEiRnLjtcF0T_xI1haD0UCuFjOA00i8I-kOyW1ASBZd2kHzhjz9KregE9is-P3z4XPww6KN-0YuXMLg-9zDABPGFdlA6GFGh7b8gtHEBNmzzjCmPUd6WCw4Z8yKgBvITULnU_DznbfeQSQWppR_ZjJADiO4-LI4GmGK-Gp_nxVfLy9uNx_L7aer6816W2pe8VQOtIJKt7ShtVKa8UFCQ7UGyaQUqho1CoFU5WX1teRMjbQWQubTCoXIW35WvNt55-B_LBhTZ03UOE3gMG-yqxoqOa1qqTK62qE6-BgDjt0cjIVw3zHa_Q2wywF2hwAz_mZvXnqLwz_4kFgG3u4Av8z_V_0BhUqqhg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607302479</pqid></control><display><type>article</type><title>Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Tamma, Pranita D ; Aitken, Samuel L ; Bonomo, Robert A ; Mathers, Amy J ; van Duin, David ; Clancy, Cornelius J</creator><creatorcontrib>Tamma, Pranita D ; Aitken, Samuel L ; Bonomo, Robert A ; Mathers, Amy J ; van Duin, David ; Clancy, Cornelius J</creatorcontrib><description>Abstract
The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase–producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of AmpC-E, CRAB, and S. maltophilia infections. Answers are presented as suggested approaches and corresponding rationales. In contrast to guidance in the previous document, published data on the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited. As such, guidance in this document is provided as “suggested approaches” based on clinical experience, expert opinion, and a review of the available literature. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Preferred and alternative treatment suggestions are provided, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Suggestions apply for both adult and pediatric populations. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 17 September 2021 and will be updated annually. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance-2.0/.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciab1013</identifier><identifier>PMID: 34864936</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Acinetobacter baumannii - drug effects ; Anti-Bacterial Agents - therapeutic use ; Bacterial Infections - drug therapy ; Bacterial Proteins ; beta-Lactamases ; Carbapenems - therapeutic use ; Drug Resistance, Bacterial ; Humans ; Microbial Sensitivity Tests ; Stenotrophomonas maltophilia - drug effects</subject><ispartof>Clinical infectious diseases, 2022-07, Vol.74 (12), p.2089-2114</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-d02a2c8060499c13d7a60cca7177592fce55e09180b47319f04557557859ee383</citedby><cites>FETCH-LOGICAL-c323t-d02a2c8060499c13d7a60cca7177592fce55e09180b47319f04557557859ee383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1583,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34864936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamma, Pranita D</creatorcontrib><creatorcontrib>Aitken, Samuel L</creatorcontrib><creatorcontrib>Bonomo, Robert A</creatorcontrib><creatorcontrib>Mathers, Amy J</creatorcontrib><creatorcontrib>van Duin, David</creatorcontrib><creatorcontrib>Clancy, Cornelius J</creatorcontrib><title>Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase–producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of AmpC-E, CRAB, and S. maltophilia infections. Answers are presented as suggested approaches and corresponding rationales. In contrast to guidance in the previous document, published data on the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited. As such, guidance in this document is provided as “suggested approaches” based on clinical experience, expert opinion, and a review of the available literature. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Preferred and alternative treatment suggestions are provided, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Suggestions apply for both adult and pediatric populations. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 17 September 2021 and will be updated annually. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance-2.0/.</description><subject>Acinetobacter baumannii - drug effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Proteins</subject><subject>beta-Lactamases</subject><subject>Carbapenems - therapeutic use</subject><subject>Drug Resistance, Bacterial</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Stenotrophomonas maltophilia - drug effects</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAQxyNERT_gxhn5BocN2HEcx8fV9oNKK4FoOUcTZ0KNYjvYzqE33qFvwnu0D8GTYLS7HJE8sq356SfN_IviNaPvGVX8gzZDLugZZfxZccIEl2UjFHue31S0Zd3y9rg4jfE7pYy1VLwojnndNrXizUnxeO1G1Mn4JZJzExEiRnLjtcF0T_xI1haD0UCuFjOA00i8I-kOyW1ASBZd2kHzhjz9KregE9is-P3z4XPww6KN-0YuXMLg-9zDABPGFdlA6GFGh7b8gtHEBNmzzjCmPUd6WCw4Z8yKgBvITULnU_DznbfeQSQWppR_ZjJADiO4-LI4GmGK-Gp_nxVfLy9uNx_L7aer6816W2pe8VQOtIJKt7ShtVKa8UFCQ7UGyaQUqho1CoFU5WX1teRMjbQWQubTCoXIW35WvNt55-B_LBhTZ03UOE3gMG-yqxoqOa1qqTK62qE6-BgDjt0cjIVw3zHa_Q2wywF2hwAz_mZvXnqLwz_4kFgG3u4Av8z_V_0BhUqqhg</recordid><startdate>20220706</startdate><enddate>20220706</enddate><creator>Tamma, Pranita D</creator><creator>Aitken, Samuel L</creator><creator>Bonomo, Robert A</creator><creator>Mathers, Amy J</creator><creator>van Duin, David</creator><creator>Clancy, Cornelius J</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220706</creationdate><title>Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections</title><author>Tamma, Pranita D ; Aitken, Samuel L ; Bonomo, Robert A ; Mathers, Amy J ; van Duin, David ; Clancy, Cornelius J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-d02a2c8060499c13d7a60cca7177592fce55e09180b47319f04557557859ee383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acinetobacter baumannii - drug effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Proteins</topic><topic>beta-Lactamases</topic><topic>Carbapenems - therapeutic use</topic><topic>Drug Resistance, Bacterial</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Stenotrophomonas maltophilia - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamma, Pranita D</creatorcontrib><creatorcontrib>Aitken, Samuel L</creatorcontrib><creatorcontrib>Bonomo, Robert A</creatorcontrib><creatorcontrib>Mathers, Amy J</creatorcontrib><creatorcontrib>van Duin, David</creatorcontrib><creatorcontrib>Clancy, Cornelius J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamma, Pranita D</au><au>Aitken, Samuel L</au><au>Bonomo, Robert A</au><au>Mathers, Amy J</au><au>van Duin, David</au><au>Clancy, Cornelius J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2022-07-06</date><risdate>2022</risdate><volume>74</volume><issue>12</issue><spage>2089</spage><epage>2114</epage><pages>2089-2114</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase–producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of AmpC-E, CRAB, and S. maltophilia infections. Answers are presented as suggested approaches and corresponding rationales. In contrast to guidance in the previous document, published data on the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited. As such, guidance in this document is provided as “suggested approaches” based on clinical experience, expert opinion, and a review of the available literature. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Preferred and alternative treatment suggestions are provided, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Suggestions apply for both adult and pediatric populations. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 17 September 2021 and will be updated annually. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance-2.0/.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34864936</pmid><doi>10.1093/cid/ciab1013</doi><tpages>26</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2022-07, Vol.74 (12), p.2089-2114 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2607302479 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acinetobacter baumannii - drug effects Anti-Bacterial Agents - therapeutic use Bacterial Infections - drug therapy Bacterial Proteins beta-Lactamases Carbapenems - therapeutic use Drug Resistance, Bacterial Humans Microbial Sensitivity Tests Stenotrophomonas maltophilia - drug effects |
| title | Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T20%3A12%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infectious%20Diseases%20Society%20of%20America%20Guidance%20on%20the%20Treatment%20of%20AmpC%20%CE%B2-Lactamase%E2%80%93Producing%20Enterobacterales,%20Carbapenem-Resistant%20Acinetobacter%20baumannii,%20and%20Stenotrophomonas%20maltophilia%20Infections&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Tamma,%20Pranita%20D&rft.date=2022-07-06&rft.volume=74&rft.issue=12&rft.spage=2089&rft.epage=2114&rft.pages=2089-2114&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciab1013&rft_dat=%3Cproquest_cross%3E2607302479%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2607302479&rft_id=info:pmid/34864936&rft_oup_id=10.1093/cid/ciab1013&rfr_iscdi=true |